Results 131 to 140 of about 4,061,047 (303)

General Medicine

open access: yes, 2008
v.531 hal.; 21 ...
Parker
core  

Variations and trends in major research topics across leading general medical journals, 1966–2022

open access: yesCritical Public Health
Attention to publication diversity calls for broader topic inclusion by journals. Although general medical journals have distinct editorial policies, cross-journal differences remain underexplored.
Nin-Chieh Hsu   +3 more
doaj   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

Generic Medicines and Branded Medicines

open access: yes
Around the world, generic prescriptions are a widely acknowledged notion. However, due to issues like unavailability and mistrust regarding the product's quality, it hasn't become as popular in India. On the other hand, the West Bengal government in India launched "fair price medicine shop" (FPMS) exclusive generic drug stores within government ...
Aarcha M R, Fathima K K
openaire   +2 more sources

PREVENTIVE MEDICINE AND THE GENERAL PRACTITIONER

open access: yesAmerican Journal of Public Health, 1925
DISCOVERIES made in the past twenty-five years regarding the causative factors of many diseases furnish a sound background for theories and practices in preventive medicine. .While most of the work in this field is being done by organized groups which function as private or public health agencies, a great deal has been said and much has been written ...
openaire   +3 more sources

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

North Texas State University Health Sciences Center/Texas College of Osteopathic Medicine: Catalog 1979-80

open access: yes, 1979
The bulletin for the Texas College of Osteopathic Medicine in the North Texas State University Health Sciences Center includes information about class offerings as well as general information about the program (academic calendar, history of the college ...
Texas College of Osteopathic Medicine
core  

Re-presenting herbal medicine as phytotherapy: a strategy of professionalisation through the formation of a 'scientific' medicine [PDF]

open access: yes, 2002
Previous research into complementary and alternative medicine has failed to accord each form of alternative medical intervention individual significance.
VanMarie, Edmund
core  

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy